Best-in-class intracellular delivery platform

Enabling next gen therapeutics through endosomal escape

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.
The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity.
This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Science

The Challenge: Endolysosomal trapping of macromolecules

One of the greatest challenges for efficacy of macromolecule therapeutics that act on an intracellular level, is delivery into key cells. Macromolecule therapeutics nowadays rely on receptor-mediated endocytosis into the endosomal compartment. The endo-lysosomal membranes, however, prohibit efficient cytoplasmic access of such foreign substances. The therapeutic efficacy of such drugs is therefore highly dependent on endo-lysosomal vesicles degradation.
Cytosolic delivery of macromolecule therapeutics requires incredibly challenging technical optimizations or specialized drug delivery platforms. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem and exposes a significant need for the development of novel delivery mechanisms.

Our Approach: ENDOSCAPE®

At Sapreme, we are developing improved macromolecule delivery mechanisms by circumventing endosomal entrapment. Our ENDOSCAPE® platform is based on compounds which can release trapped cargo from the endo-lysosomal membranes, improving the therapeutic window and enabling access to intracellular targets with minimal toxicity.
By binding our technology to antibody-conjugated toxins and oligonucleotides, our goal is to enhance target engagement and improve therapeutic efficacy without limitation to biologic modality or indication.

News & Events

Events:

Upcoming events:
2023 BIO International Convention, Boston, 5-8 June

Meet us at BIO 2023 in Boston! In the week of 5-8 June, our CEO Guy Hermans will represent Sapreme and participate in the one-on-one partnering meetings.

If you would like to learn more about our targeted, intracellular delivery technology and discuss how we might collaborate and enable efficient delivery of your intracellular RNA or protein therapeutics, please get in touch!

4th RNA Editing Summit 2023, Boston, 11-13 July

Sapreme’s Chief Development Officer Miriam Bujny will be present at the 4th RNA Editing Summit in Boston. If you find yourself there July 11 to 13, be sure not to miss her talk on in vitro and in vivo performance of Sapreme’s endosomal escape enhancers, with broad applicability for targeted RNA- and protein therapeutics.

And should you not participate to the conference, don’t hesitate to reach out and schedule a meeting outside the conference!

Past events:
8 – 9 March, 2023 | Boston, MA – Targeted Intracellular Delivery Summit

We will be delivering a talk at the first Targeted Intracellular Delivery Summit, in which Sapreme’s highly differentiated tissue specific targeted, intracellular delivery technology will be highlighted.  The Targeted Intracellular Delivery Summit is a new and unique industry touchpoint for optimising the therapeutic index of complex-payload pipelines through novel targeted delivery systems & overcoming critical endosomal biological barriers.  We look forward to sharing our insights and meeting up with the many other trailblazers, current and potential future partners in Boston in March.

9 – 11 January, 2023 | San Francisco- JP Morgan Week | Bio 2023

Guy Hermans (CEO) will be returning to San Francisco to represent Sapreme during JPM week. He is looking forward to discuss our recent achievements and is  welcoming opportunities to meet current and future partners to explain our delivery technology and explore how we might collaborate together. Meeting requests are best send through the Bio Partnering system, or send a message to info@sapreme-technologies.com.

Press Releases:

Archive Press Releases

 

About Sapreme:

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contacts: Guy Hermans, CEO   |  +31 30 760 09 76   |  hermans@sapreme-technologies.com

For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher  |  +49 89 238 877 30  |  sapreme@trophic.eu

Careers

Sapreme Technologies is a privately-owned biotech company developing a disruptive technology platform (ENDOSCAPE®) enabling the development of superior targeted therapeutics, such as antibody-drug conjugates and oligonucleotide-based drugs. Our latest vacancies have recently been filled successfully. There are no  openings at this time. New opportunities will be announced here, and on Sapreme’s linkedin page.

Open applications welcome

If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76

Address

Antonie van Leeuwenhoeklaan 9
USP Bilthoven A12-1
3721 MA Bilthoven
The Netherlands

E-mail

info@sapreme-technologies.com